clemastine has been researched along with desloratadine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Döbbeling, U; Graf, N; Johansen, P; Kündig, TM; Waeckerle-Men, Y; Zabel, F | 1 |
1 review(s) available for clemastine and desloratadine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for clemastine and desloratadine
| Article | Year |
|---|---|
The antihistamines clemastine and desloratadine inhibit STAT3 and c-Myc activities and induce apoptosis in cutaneous T-cell lymphoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Clemastine; Cytoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Histamine Antagonists; Humans; Loratadine; Lymphoma, T-Cell, Cutaneous; Proto-Oncogene Proteins c-myc; STAT3 Transcription Factor | 2013 |